Anthera Pharmaceuticals (ANTH)
Anthera Pharmaceuticals Revenues
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
About Revenues
Income that a company gains from business activities, calculated before any expenses are subtracted. Includes all sales and other increases in owner's equity.
Learn More
You may also be interested in these ANTH related companies
ANTH News
Canaccord Genuity Reiterates a 'Buy' on Anthera Pharma (ANTH); All Eyes on June Phase 2 Data
May 07, 9:07AM Street Insider
May 07, 9:07AM Street Insider
Anthera Pharmaceuticals Reports 2012 First Quarter Financial Results And Provides Clinical Progress Update
May 03, 5:00PM PR Newswire
May 03, 5:00PM PR Newswire
Anthera Announces First Quarter 2012 Financial Report and Conference Call
Apr 27, 12:00PM PR Newswire
Apr 27, 12:00PM PR Newswire
Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
Apr 25, 2:30PM Benzinga
Apr 25, 2:30PM Benzinga
Shorted $ANTH @ 2.63. Currently 2.41--looking for 2.33 with a stop at 2.50.
about 38 days ago by 228investing
about 38 days ago by 228investing
$ANTH buyers today...Been holding for a few weeks now for LUPUS data due mid year...This could be a flyer
about 39 days ago by holiday613
about 39 days ago by holiday613
Anthera Pharmaceuticals to Present at the BioCentury Future Leaders Conference
Apr 17, 3:00PM PR Newswire
Apr 17, 3:00PM PR Newswire
Love the accumulation in $ANTH last few days..positive divergence from overall down mkt..Me thinks the bottom is in
about 52 days ago by holiday613
about 52 days ago by holiday613
$ANTH basing very nicely here...Lupus data due mid year..Looks like an easy double from here imo
about 52 days ago by holiday613
about 52 days ago by holiday613
$ANTH .Started accumulating a position today..The cheapest play on Lupus that i can see .
about 55 days ago by holiday613
about 55 days ago by holiday613
$ANTH filed latest Proxy Statement with the SEC (Form DEF 14A) http://stks.co/38sq
about 59 days ago by MarketBrief
about 59 days ago by MarketBrief
Canaccord Genuity Reiterates a 'Buy' on Anthera Pharma (ANTH); Expectations for June Phase 2 PEARL Trial
Mar 29, 8:40AM Street Insider
Mar 29, 8:40AM Street Insider
Canaccord Genuity Reiterates a 'Buy' on Anthera Pharma (ANTH); Looking Ahead to Other B-Mod Programs
Mar 19, 8:51AM Street Insider
Mar 19, 8:51AM Street Insider
Anthera Pharmaceuticals (ANTH) Cuts 45% of Workforce After Termination of VISTA-16 Study
Mar 15, 5:05PM Street Insider
Mar 15, 5:05PM Street Insider
Anthera Pharma (ANTH) Crushed on Plans to Stop VISTA-16 Trial Due to Lack of Efficacy
Mar 12, 10:52AM Street Insider
Mar 12, 10:52AM Street Insider
Canaccord Genuity Maintains a 'Buy' on Anthera Pharma (ANTH); Hard Stop to Varespledib/A001 Development
Mar 12, 8:36AM Street Insider
Mar 12, 8:36AM Street Insider
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| ANTH | 1.85 | -0.06 | -3.14% | 75.83M |
| ANSS | 62.09 | +0.40 | +0.65% | 5.761B |
| ANR | 11.17 | +0.00 | +0.00% | 2.458B |
| ANO | 0.298 | +0.00 | +0.00% | 60.16M |
| AIV | 26.71 | -0.04 | -0.15% | 3.237B |
| AIT | 37.16 | -0.13 | -0.35% | 1.561B |
| AIS | 2.89 | +0.02 | +0.70% | 299.69M |
| AIRT | 9.250 | +0.17 | +1.87% | 22.66M |
| AIRM | 91.97 | -0.12 | -0.13% | 1.159B |
| AIR | 12.48 | -0.29 | -2.27% | 502.69M |
